Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.73 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.73 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.73 |
| ▸ | FAP | Q12884 | 4/20 | 0.73 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693335 | 0.85 | DPP4 (0.65) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL14973464 | 0.85 | DPP4 (0.69) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL14421643 | 0.83 | DPP4 (0.71) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL14535255 | 0.82 | DPP4 (0.77) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL14535419 | 0.82 | DPP4 (0.64) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL14421644 | 0.82 | DPP4 (0.74) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL6685925 | 0.81 | DPP4 (0.52) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6692186 | 0.80 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6686205 | 0.80 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8377973 | 0.80 | DPP4 (0.94) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406872-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1406872-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7098239-B2 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC (US) | 2006-08-29 | — | — | US | disclosed |
| US-20040176428-A1 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176428-A1 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | DPP4, DPP3, DPP9 | DPP4 1/4885DPP8 6/4885DPP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.